Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
68500 participants
OBSERVATIONAL
2022-07-01
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Is long-term CCB use associated with the development of breast cancer amongst women enrolled in three longitudinal cohort studies in Australia and the Netherlands and what is the dose-response nature of this association.
* Does differences in the association between calcium channel blocker use and the development of breast cancer exist between Australian and Dutch women.
The investigators will utilise data from the Australian Longitudinal Study on Women's Health (ALSWH) , 45 and Up Study and Rotterdam study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
NCT05941520
Coagulation Parameters in Postmenopausal Breast Cancer Patients Under Adjuvant Hormonal Therapy
NCT00814034
Breast Density, Hormone Levels, and Anticancer Drug Levels in Women With Invasive Breast Cancer Who Are Receiving Exemestane or Anastrozole
NCT00316836
Evaluating the Effect of Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity
NCT00459771
Study of Breast Cancer Prevention by Letrozole in High Risk Women
NCT00579826
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Data sources: the Australian Longitudinal Study on Women's Health , 45 and Up Study, Rotterdam study and linked administrative data.
Study cohort: Women with self-reported hypertension (HTN) without prior breast cancer.
Harmonisation: Relevant variables will be checked for harmonisation in which variables available in all three cohort will be used in the harmonised analysis. The variables will be checked on the definition, measurement and harmonisation rules. Variables that cannot be harmonised across the cohorts will be used in the cohort specific analyses.
Exposure measurement: The primary exposure is the use of CCB, which will be identified by the anatomical therapeutic chemical code (C08) in the medicine data. Exposure to CCB as well as other antihypertensive (AHT) medicines will be captured separately as the cumulative dose-duration of exposure during follow up. Participants will be stratified in four groups: women with HTN with no AHT use, women with HTN exposed to CCB only, women with HTN exposed to non-CCB and women with HTN exposed to both CCB and non-CCB.
Outcome measurement: Data on a diagnosis of invasive breast cancer will be obtained from cancer registries and hospital admission data using ICD-10 code of C50.x.
Potential confounders: age, education, marital status, socioeconomic status, body mass index, diabetes, heart disease, stroke, age when had first child, parity, history of hysterectomy or oophorectomy, use of hormonal contraception, use of hormonal replacement therapy.
Statistical analysis: The association between CCB use and breast cancer risk will be estimated by the Fine and Gray competing risk regression model in which a first diagnosis of invasive breast cancer will be treated as the principle event and death and bilateral mastectomy (without a diagnosis of breast cancer) will be competing risks. The nonlinear threshold models will be used to capture any differential effect of the cumulative dose-duration of CCB while simultaneously accounting for the cumulative dose-duration of other AHT exposure on breast cancer risk. Other confounders will be accounted for in the models using propensity scores.
Implications: Results from this study will contribute to addressing the concerns about using CCB for hypertension treatment in women, particularly in those who have high risk of breast cancer.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
No AHT
Women with HTN with no AHT use
None AHT
None AHT
AHT but non-CCB
Women with HTN exposed to other antihypertensive medicines but not exposed to calcium channel blockers
Beta blocker
Drugs with ATC code C07 will be categorised as beta-blockers.
Diuretic
Drugs with ATC code C03 will be categorised as diuretics.
RAS
Drugs with ATC code C09 will be categorised as RAS (agents acting on the renin angiotensin system).
Other AHT
Drugs with ATC code C02 will be categorised as other antihypertensives.
CCB only
Women with HTN exposed to calcium channel blockers but not exposed to other antihypertensive medicines
Calcium channel blocker
Drugs with ATC code C08 will be categorised as calcium channel blockers.
Both CCB and non-CCB
Women with HTN exposed to both calcium channel blockers and other antihypertensive medicines.
Calcium channel blocker
Drugs with ATC code C08 will be categorised as calcium channel blockers.
Beta blocker
Drugs with ATC code C07 will be categorised as beta-blockers.
Diuretic
Drugs with ATC code C03 will be categorised as diuretics.
RAS
Drugs with ATC code C09 will be categorised as RAS (agents acting on the renin angiotensin system).
Other AHT
Drugs with ATC code C02 will be categorised as other antihypertensives.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Calcium channel blocker
Drugs with ATC code C08 will be categorised as calcium channel blockers.
Beta blocker
Drugs with ATC code C07 will be categorised as beta-blockers.
Diuretic
Drugs with ATC code C03 will be categorised as diuretics.
RAS
Drugs with ATC code C09 will be categorised as RAS (agents acting on the renin angiotensin system).
Other AHT
Drugs with ATC code C02 will be categorised as other antihypertensives.
None AHT
None AHT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Self-reported/diagnosed hypertension at study entry.
Exclusion Criteria
45 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Curtin University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rachael Moorin
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Curtin university
Bentley, Western Australia, Australia
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ho C, Ha NT, Youens D, Abhayaratna WP, Bulsara MK, Hughes JD, Mishra G, Pearson SA, Preen DB, Reid CM, Ruiter R, Saunders CM, Stricker BH, van Rooij FJA, Wright C, Moorin R. Association between long-term use of calcium channel blockers (CCB) and the risk of breast cancer: a retrospective longitudinal observational study protocol. BMJ Open. 2024 Mar 8;14(3):e080982. doi: 10.1136/bmjopen-2023-080982.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2014896
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.